NEUROCRINE BIOSCIENCES INC — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Neurocrine reported Q3 2026 total revenues of $1,123M (41% YoY growth), with INGREZZA net sales of $801M (+17% YoY), CRENESSITY $211M (+115%), and VYKAT XR $107M (first full quarter post-Soleno acquisition in May 2026). The company raised full-year 2026 INGREZZA guidance from $2,825–$2,875M to $2,900–$2,925M. Q3 GAAP net income was $207M ($1.96 EPS); Non-GAAP net income was $347M ($3.29 EPS, +52% YoY). Cash position declined from $2,543M (end-2025) to $790M (Sept 30, 2026), reflecting the Soleno acquisition spend and $2.2B in intangible assets recorded for VYKAT XR IP.
Why this rating
Strong organic revenue growth (41% YoY) and raised INGREZZA guidance demonstrate durable demand. VYKAT XR contributes new revenue stream. However, cash burn ($1.75B YTD decline) and Soleno integration risks are material headwinds relative to $9.5B market cap.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.